MARKET

MTEM

MTEM

Molecular US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.21
-0.86
-7.77%
After Hours: 10.21 0 0.00% 16:00 10/20 EDT
OPEN
11.10
PREV CLOSE
11.07
HIGH
11.15
LOW
10.15
VOLUME
233.18K
TURNOVER
--
52 WEEK HIGH
19.12
52 WEEK LOW
6.80
MARKET CAP
509.68M
P/E (TTM)
-3.9401
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Have Never Been This Bullish On Molecular Templates, Inc. (MTEM)
Insider Monkey · 10/07 17:47
Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 10/05 19:27
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
\- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -\- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions -MENLO PARK, Calif. and GREENWICH
GlobeNewswire · 09/23 12:00
Molecular Templates (MTEM) Investor Presentation - Slideshow
The following slide deck was published by Molecular Templates, Inc. in conjunction with this event.
Seekingalpha · 09/21 21:14
Molecular Templates to Participate in September Virtual Investor Conferences
AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted
GlobeNewswire · 09/03 13:00
How Many Molecular Templates, Inc. (NASDAQ:MTEM) Shares Do Institutions Own?
Simply Wall St. · 08/20 17:34
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings: Kura Oncology (NASDAQ:KURA): $300M. Alphatec Holdings (NASDAQ:ATEC): $200M. Dynava
seekingalpha · 08/07 16:33
Molecular Templates EPS misses by $0.32, beats on revenue
Molecular Templates (NASDAQ:MTEM): Q2 GAAP EPS of -$0.68 misses by $0.32. Revenue of $6.91M (+26.8% Y/Y) beats by $1.89M. Press Release
seekingalpha · 08/07 02:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTEM. Analyze the recent business situations of Molecular US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTEM stock price target is 23.14 with a high estimate of 34.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 27.36M
% Owned: 54.81%
Shares Outstanding: 49.92M
TypeInstitutionsShares
Increased
46
3.90M
New
30
333.23K
Decreased
20
2.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.90%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/Director
Harold Selick
President/Chief Operating Officer
Jason Kim
Chief Executive Officer/Chief Scientific Officer/Director
Eric Poma
Chief Financial Officer/Treasurer/Secretary
Adam Cutler
Other
Roger Waltzman
Independent Director
David Hirsch
Independent Director
David Hoffmann
Independent Director
Kevin Lalande
Independent Director
Jonathan Lanfear
Independent Director
Scott Morenstein
Independent Director
Corazon Sanders
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MTEM
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.